FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2309445729> ?p ?o ?g. }

• W2309445729 endingPage "e1101205" @default.
• W2309445729 startingPage "e1101205" @default.
• W2309445729 abstract "Thymidylate synthase (TS) is a tumor-associated enzyme critical for DNA replication and main 5′-fluorouracil (5′-FU) target. TSPP/VAC1 is a multi-arm trial phase-Ib trial program aimed to investigate the toxicity and biomodulatory activity of a poly-epitope-peptide vaccine to TS (TSPP) in cancer patients (pts). Here, we present the results of the TSPP/VAC1/arm C trial aimed to evaluate TSPP in combination with chemo-immunotherapy in pretreated metastatic colo-rectal cancer (mCRC) pts. Twenty-nine pts, 14 males and 15 females, received poly-chemotherapy with gemcitabine [GEM; 1,000 mg/sqm, day-1], oxaliplatin [OX; 80 mg/sqm, day-2], levofolinate [100 mg/sqm, days 1–2], bolus/infusional 5′-FU [400 mg/800 mg/sqm, days 1–2], sargramostim [50 μg, days 3–7/q30], and interleukin-2 [sc. 0.5 MIU twice a day, days 8–14/18–30] [GOLFIG-regimen]. Seventeen pts received sc. TSPP injections at escalating dosage [3 pts, 100 µg (DL-1); 3 pts, 200 µg (DL-2) and 11pts, 300 µg (DL-3)] one week after each chemotherapy cycle (concomitant module), while 10 out 12 pts received TSPP (300 µg) after 12 GOLFIG courses [dose level (DL)-0] (sequential module). TSPP MTD was not achieved. Adverse events consisted in swelling/erythema at injection sites (17 cases), G1–2 haematological (16 cases) and gastro-enteric events (12), fever, rhinitis, conjunctivitis, and poly-arthralgia and rise in auto-antibodies [ANA, ENA, c-ANCA, p-ANCA in the DL1–3 pts]. Both treatment-modules showed immunomodulating and antitumor activity (disease-control-rate, DL1–3 and DL0 were 70.6% and 83.3%, respectively) with a better survival recorded in the second group [median OS DL1–3 vs. DL0 = 8 vs. 16 mo, p = 0.049]. The promising long-term survival produced by the sequential treatment module deserves further phase II evaluation." @default.
• W2309445729 created "2016-06-24" @default.
• W2309445729 creator A5000930768 @default.
• W2309445729 creator A5007677152 @default.
• W2309445729 creator A5018043620 @default.
• W2309445729 creator A5018403925 @default.
• W2309445729 creator A5021887337 @default.
• W2309445729 creator A5029614536 @default.
• W2309445729 creator A5030302760 @default.
• W2309445729 creator A5034001084 @default.
• W2309445729 creator A5038022203 @default.
• W2309445729 creator A5057162212 @default.
• W2309445729 creator A5057193918 @default.
• W2309445729 creator A5066343209 @default.
• W2309445729 creator A5075776316 @default.
• W2309445729 creator A5080281985 @default.
• W2309445729 creator A5083605871 @default.
• W2309445729 creator A5085661524 @default.
• W2309445729 creator A5088955056 @default.
• W2309445729 date "2015-12-21" @default.
• W2309445729 modified "2023-10-18" @default.
• W2309445729 title "Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients" @default.
• W2309445729 cites W118656858 @default.
• W2309445729 cites W144924280 @default.
• W2309445729 cites W1607544571 @default.
• W2309445729 cites W1963731263 @default.
• W2309445729 cites W1967994686 @default.
• W2309445729 cites W1974718705 @default.
• W2309445729 cites W1976171528 @default.
• W2309445729 cites W1977632329 @default.
• W2309445729 cites W1982906652 @default.
• W2309445729 cites W1991842105 @default.
• W2309445729 cites W2002952328 @default.
• W2309445729 cites W2003606772 @default.
• W2309445729 cites W2003831736 @default.
• W2309445729 cites W2014993834 @default.
• W2309445729 cites W2020064216 @default.
• W2309445729 cites W2022595565 @default.
• W2309445729 cites W2022990363 @default.
• W2309445729 cites W2037754934 @default.
• W2309445729 cites W2041221416 @default.
• W2309445729 cites W2041389044 @default.
• W2309445729 cites W2050531099 @default.
• W2309445729 cites W2060094878 @default.
• W2309445729 cites W2068074068 @default.
• W2309445729 cites W2081195304 @default.
• W2309445729 cites W2088206187 @default.
• W2309445729 cites W2113847305 @default.
• W2309445729 cites W2123105952 @default.
• W2309445729 cites W2133620794 @default.
• W2309445729 cites W2138753037 @default.
• W2309445729 cites W2142052493 @default.
• W2309445729 cites W2144248058 @default.
• W2309445729 cites W2148226248 @default.
• W2309445729 cites W2149889388 @default.
• W2309445729 cites W2157939496 @default.
• W2309445729 cites W2316518752 @default.
• W2309445729 cites W4211140292 @default.
• W2309445729 cites W643705383 @default.
• W2309445729 doi "https://doi.org/10.1080/2162402x.2015.1101205" @default.
• W2309445729 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4839351" @default.
• W2309445729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27141384" @default.
• W2309445729 hasPublicationYear "2015" @default.
• W2309445729 type Work @default.
• W2309445729 sameAs 2309445729 @default.
• W2309445729 citedByCount "24" @default.
• W2309445729 countsByYear W23094457292016 @default.
• W2309445729 countsByYear W23094457292017 @default.
• W2309445729 countsByYear W23094457292018 @default.
• W2309445729 countsByYear W23094457292019 @default.
• W2309445729 countsByYear W23094457292020 @default.
• W2309445729 countsByYear W23094457292021 @default.
• W2309445729 countsByYear W23094457292022 @default.
• W2309445729 crossrefType "journal-article" @default.
• W2309445729 hasAuthorship W2309445729A5000930768 @default.
• W2309445729 hasAuthorship W2309445729A5007677152 @default.
• W2309445729 hasAuthorship W2309445729A5018043620 @default.
• W2309445729 hasAuthorship W2309445729A5018403925 @default.
• W2309445729 hasAuthorship W2309445729A5021887337 @default.
• W2309445729 hasAuthorship W2309445729A5029614536 @default.
• W2309445729 hasAuthorship W2309445729A5030302760 @default.
• W2309445729 hasAuthorship W2309445729A5034001084 @default.
• W2309445729 hasAuthorship W2309445729A5038022203 @default.
• W2309445729 hasAuthorship W2309445729A5057162212 @default.
• W2309445729 hasAuthorship W2309445729A5057193918 @default.
• W2309445729 hasAuthorship W2309445729A5066343209 @default.
• W2309445729 hasAuthorship W2309445729A5075776316 @default.
• W2309445729 hasAuthorship W2309445729A5080281985 @default.
• W2309445729 hasAuthorship W2309445729A5083605871 @default.
• W2309445729 hasAuthorship W2309445729A5085661524 @default.
• W2309445729 hasAuthorship W2309445729A5088955056 @default.
• W2309445729 hasBestOaLocation W23094457291 @default.
• W2309445729 hasConcept C121608353 @default.
• W2309445729 hasConcept C123321153 @default.
• W2309445729 hasConcept C126322002 @default.
• W2309445729 hasConcept C143998085 @default.
• W2309445729 hasConcept C2776694085 @default.
• W2309445729 hasConcept C2779384505 @default.

• next